Additionally, more than 60% of the cases across the different subtypes showed mainly weak-to-moderate immunoreactivity for nucleolin (light gray to dark gray) in TEC, TIL, and CAF nuclear localization, except for SQ carcinomas (41.7%), whereas at least 17% to 33% of the cases showed low/negative nucleolin immunoreactivity. The gene discussed is NUCLEOLIN; the disease is carcinoma.